Prostate Cancer

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.

Surgery has its side effects, says radiation oncologist Richard Stock, including possible incontinence and sexual dysfunction. While radiation is less invasive, it does have its own side effects.

Treatment with Xtandi reduced the risk of progression by 76 percent compared with bicalutamide in men with castration-resistant prostate cancer, according to topline results from the phase 2 STRIVE study.

The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network, explains active surveillance when it comes to a prostate cancer diagnosis.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press.

Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared with those without a history of testicular cancer.

Bill that would create a National Prostate Cancer Council—charged with creating a plan for the screening, diagnosis and monitoring of prostate cancer—was introduced Jan. 21 by Sen. Barbara Boxer.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.

Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.

Raoul Concepcion, a urologist with Urology Associates in Nashville, Tenn., explains Gleason score and Gleason grade as it relates to a prostate cancer diagnosis.

Men undergoing prostate cancer treatment should give special attention to ensuring good pelvic floor strength in order to reduce side effects of treatment and maximize urinary and sexual function.

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

Prostate cancer drug Xtandi, as well as the blood cancer drug Imbruvica, may help additional patients with these cancers.

What began as an awareness campaign—men sporting mustaches in November in support of men's health—now has spurred one of the largest investments in improving the quality of life for men with prostate cancer.

Several studies announcing the latest research in different cancers, including prostate, breast and lung cancers, were presented at the 2014 European Society of Medical Oncology's annual meeting in Madrid, Spain.

Whether to opt for surgery or radiation to treat localized prostate cancer depends mainly on the stage and grade of disease, but both therapies are acceptable forms of treatment.

Maintaining bone health is essential throughout cancer treatment.

Updates from ASCO's Genitourinary Cancers Symposium.

Reel Recovery offers free fly-fishing retreats for men recovering from cancer.

Patients should research both the surgeon and the technique when deciding on treatment.

Dietary supplement Pomi-T lowers biomarker levels associated with prostate cancer.